STAT3 and glioma: Our findings also show that IL-6 and miR-155-3p may be novel biomarkers for diagnosing glioma and that treatment targeting autophagy and the STAT3 pathway may impair the immunosuppressive tumor microenvironment and participate in antitumor immunotherapy.